Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc.

  1. October 21, 2025

    Regeneron, Rival End Patent Fight Over Eye Med Biosimilar

    Regeneron and a South Korea-based rival it had accused of infringing several patents covering the U.S. biotech company's top eye medication Eylea have agreed to a settlement to put an end to the case filed in West Virginia federal court.

  2. November 09, 2023

    Regeneron Hits Rival With Patent Suit Over Eye Med Generic

    Regeneron accused a South Korea-based rival of infringing a slew of patents covering the American biotech company's top eye medication in a new lawsuit filed in West Virginia, claiming that its Eylea product has exclusivity until mid-2024.